文献速递基础与转化研究新药、器械与细胞基因治疗研发

CD19 CAR-T细胞治疗后发生侵袭性淋巴瘤

Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
PubMed 文献 · N Engl J Med · 2024-01-01

一例复发原发性中枢神经系统淋巴瘤患者接受替沙来仑赛治疗后1个月发生致死性克隆性自主增殖的CD4-CD8-CAR+外周T细胞淋巴瘤。该淋巴瘤的克隆性T细胞受体重排早在CAR-T制备的白细胞分离产物中及7个月前自体移植时即可检出,提示克隆性造血参与淋巴瘤发生。

要点

  • 接受替沙来仑赛治疗1个月后发生致死性CD4-CD8-CAR+外周T细胞淋巴瘤。
  • 淋巴瘤的克隆性T细胞受体重排在CAR-T制备的白细胞分离产物中已可检出。
  • DNMT3A和TET2突变在CD34+干细胞及其后代、白细胞分离标本和自体移植物中均检出。

核心结论

  • CD19 CAR-T细胞治疗后发生致死性克隆性CD4-CD8-CAR+外周T细胞淋巴瘤,克隆性造血参与其发生。

研究设计与样本

  • 病例报告:一例复发原发性中枢神经系统淋巴瘤患者接受替沙来仑赛治疗后发生外周T细胞淋巴瘤。

主要发现

  • 该外周T细胞淋巴瘤为致死性、克隆性、自主增殖的CD4-CD8-CAR+肿瘤,发生于替沙来仑赛治疗后1个月。
  • 淋巴瘤具有克隆性T细胞受体重排,在CAR-T制备的白细胞分离产物中及7个月前自体移植时已可检出。
  • CD34+干细胞及其后代中的体细胞DNMT3A和TET2突变在淋巴瘤、CAR-T制备的白细胞分离标本和自体移植物中均检出。
  • 淋巴瘤携带额外的体细胞TET2突变,在CAR-T白细胞分离产物和最终CAR-T产品中以极低频率可检出。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary central nervous system lymphoma. The PTCL had a clonal T-cell receptor rearrangement, which was already detectable in the apheresis product for CAR T-cell manufacturing and 7 months earlier for autologous transplantation. Somatic DNMT3A and TET2 mutations in CD34+ stem cells and their progeny were detected in the PTCL, in the apheresis specimen that was obtained for CAR T-cell production, and in the autotransplant. The PTCL harbored an additional somatic TET2 mutation, which was already detectable in the CAR T-cell apheresis product and the final CAR T-cell product at very low frequencies, providing evidence that clonal hematopoiesis had contributed to lymphomagenesis.

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Kobbe G, Brüggemann M, Baermann BN, et al. Aggressive Lymphoma after CD19 CAR T-Cell Therapy. N Engl J Med. 2024. PMID: 39589371. doi:10.1056/NEJMoa2402730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。